AI in Action: Opening the Door for Novel Treatments in Schizophrenia
Using data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study — the largest antipsychotics trial ever conducted — BullFrog AI performed a clustering analysis in which bfLEAP™ identified key correlates of poor outcomes in response to olanzapine, an anti-psychotic drug used to treat schizophrenia. Highlighting novel genetic biomarkers of patient response to drug treatment, this analysis establishes a significant proof of work for the bfLEAP™ platform.
Discover the true potential of your drug discovery and development program with bfLEAP™.
